Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Alikian

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
British Journal of Haematology|October 15, 2013
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemiaJacob Grinfeld, Gareth Gerrard, Mary Alikian, et al.
Haematologica|May 11, 2019
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitorsGeorgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, et al.
Frontiers in Immunology|March 25, 2021
Identification of Reduced Host Transcriptomic Signatures for Tuberculosis Disease and Digital PCR-Based Validation and QuantificationHarriet D Gliddon, Myrsini Kaforou, Mary Alikian, et al.
Journal of Medicinal Chemistry|November 18, 2010
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administrationDean A Heathcote, Hetal Patel, Sebastian H B Kroll, et al.
Blood|December 11, 2012
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationshipsJamshid S Khorashad, Todd W Kelley, Philippe Szankasi, et al.
American Journal of Medical Genetics. Part A|December 14, 2021
Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformationsSrimmitha Balachandar, Tamara J Graves, Anika Shimonty, et al.
Journal of Medical Genetics|March 15, 2020
Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary networkAlice Garrett, Alison Callaway, Miranda Durkie, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
British Journal of Haematology|October 15, 2013
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemiaJacob Grinfeld, Gareth Gerrard, Mary Alikian, et al.
Haematologica|May 11, 2019
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitorsGeorgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, et al.
Frontiers in Immunology|March 25, 2021
Identification of Reduced Host Transcriptomic Signatures for Tuberculosis Disease and Digital PCR-Based Validation and QuantificationHarriet D Gliddon, Myrsini Kaforou, Mary Alikian, et al.
Journal of Medicinal Chemistry|November 18, 2010
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administrationDean A Heathcote, Hetal Patel, Sebastian H B Kroll, et al.
Blood|December 11, 2012
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationshipsJamshid S Khorashad, Todd W Kelley, Philippe Szankasi, et al.
American Journal of Medical Genetics. Part A|December 14, 2021
Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformationsSrimmitha Balachandar, Tamara J Graves, Anika Shimonty, et al.
Journal of Medical Genetics|March 15, 2020
Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary networkAlice Garrett, Alison Callaway, Miranda Durkie, et al.
Pageof 2